Fairness and efficiency considerations in COVID-19 vaccine allocation strategies: a case study comparing front-line workers and 65-74 year olds in the United States

Competing Interest Statement

Eva Rumpler has no conflicts of interest to disclose. Justin Feldman reports grants to institution from the Robert Wood Johnson Foundation and payments from the New York City Department of Health & Mental Hygiene and employment by the Center for Policing Equity. Mary Bassett reports grants to institution from the Robert Wood Johnson Foundation. Marc Lipsitch reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer, personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside the submitted work; and unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, COVAX (United Biomedical).

Funding Statement

ER and ML were supported by the Morris-Singer Fund. This work was supported in part by Award Number U01CA261277 from the US National Cancer Institute of the National Institutes of Health. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the Morris-Singer Fund or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involves only openly available data obtained from the American Community Survey (ACS) and the National Center for Health Statistics (NCHS), which can be obtained from https://data.cdc.gov/NCHS/Deaths-involving-coronavirus-disease-2019-COVID-19/ks3g-spdg, https://data.cdc.gov/NCHS/NVSS-Provisional-COVID-19-Deaths-by-Place-of-Death/4va6-ph5s, and https://www.census.gov/programs-surveys/acs/data.html.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes